חוב לטווח ארוך: Cullinan Therapeutics Inc (CGEM)

The current market value shown on this chart helps assess the stability of Cullinan Therapeutics (CGEM), whose success is based on trials of the CLN-619 drug. Cullinan Therapeutics (CGEM) is implementing AI-driven design to accelerate the selection of global molecules. Platform development relies on early test results, and the debt load ratio stands at 0.00. Despite intensive expenditures, the current liquidity reserve remains within safe limits.

For Cullinan Therapeutics (CGEM), which is developing a targeted tumor therapy platform, this indicator determines the volume of borrowed funds with a maturity of more than one year. The metric measures the business's fundamental dependence on creditors, allowing for an assessment of default risk and the issuer's financial autonomy. By analyzing the company's long-term debt structure, an investor can see the balance between borrowed capital and operational stability. Minimal debt combined with partnerships with pharma behemoths confirms the company's ability to fund development through external payments.